Semaglutide Benefits: What the Evidence Actually Shows

By Victor Björk

Semaglutide is the most thoroughly validated pharmacological weight-loss agent in the history of clinical medicine, and the people most likely to undersell it are the same researchers who produced the data. The trials are large, the effect sizes are real, and the cardiovascular signal extends well beyond what adiposity reduction alone can explain. Several of the most frequently repeated claims about how semaglutide works at the molecular level, however, remain preclinical speculation dressed up as established mechanism, and the safety picture beyond five years of continuous exposure is genuinely unknown. Conflating the strong evidence with the weak does no one any favors.

What the Major Trials Actually Found

Several claims in the original outline for this article could not be supported by independently verified citations, so they will not appear here as hard numbers. The STEP 1, SUSTAIN-6, SELECT, and FLOW trials are real and the direction of their findings is not in dispute, but citing specific effect sizes without a verified primary source would be exactly the kind of confident assertion this article is arguing against.

What the verified literature does show is substantial on its own terms.

Nephroprotection across the drug class. A 2026 meta-analysis of 19 randomized controlled trials enrolling 90,882 patients found that GLP-1 receptor agonists as a class reduced composite renal outcomes by 19% (RR 0.81) and microalbuminuria by 24% (RR 0.76) in patients with and without diabetes. [1] The FLOW trial, which tested semaglutide 1 mg specifically in patients with type 2 diabetes and established chronic kidney disease, sits within this broader class effect. Whether semaglutide’s renal benefit is meaningfully larger than that of older agents like dulaglutide or liraglutide remains an open question the meta-analysis could not cleanly resolve.

Cardiovascular benefit in people without diabetes. The SELECT trial’s enrollment of over 17,000 overweight or obese adults without diabetes was a deliberate attempt to isolate the cardiovascular signal from the glycemic one. That the benefit persisted in this population matters enormously for mechanism: you cannot attribute a cardiovascular risk reduction to improved glycemic control in people who did not have disordered glycemia to begin with.

The implication most commentators miss: if the cardiovascular benefit in SELECT is real and is not mediated by glucose lowering, then GLP-1 receptor signaling is doing something to vascular or inflammatory biology that we have not yet cleanly characterized in humans.

Mechanism: What’s Established vs. What’s Still Rodent Data

The pancreatic mechanism is not in dispute. Semaglutide binds the GLP-1 receptor on pancreatic beta cells, stimulates insulin secretion in a glucose-dependent manner, and suppresses glucagon during hyperglycemia. This has been confirmed in receptor-knockout animal models and human euglycemic clamp studies. [2] The glucose-dependence of insulin secretion is what separates GLP-1 receptor agonists from sulfonylureas pharmacologically, and it is the reason hypoglycemia rates in the trials are so low in people without concurrent insulin use.

Central appetite suppression is also reasonably well characterized. GLP-1 receptors are expressed in the hypothalamus and in the brainstem area postrema, and a 2024 review in Signal Transduction and Targeted Therapy describes GLP-1R expression across multiple human tissue types including the nervous system, with downstream effects on reward-circuit activity and satiety signaling. [3] This is consistent with the clinical observation that patients on semaglutide report reduced food preoccupation rather than simply feeling fuller.

The anti-inflammatory story is where the extrapolation starts to outrun the data. A 2026 review found that GLP-1 receptor agonists improve inflammatory biomarkers including IL-6 and high-sensitivity CRP, and show effects on carotid intima-media thickness in obesity and subclinical atherosclerosis. [4] That review is honest about the limitation: the evidence is mixed between cell-line work, rodent models, and human observational data, and separating a direct endothelial effect from the downstream consequences of losing 15% of body weight is methodologically very hard. The NF-κB signaling and macrophage foam-cell formation data cited most often in this context come from cell culture and rodents, and applying those findings to humans as though the mechanism is confirmed is premature.

This is worth comparing to the early EGF (epidermal growth factor) story. EGF’s role in promoting gastrointestinal mucosal growth in neonates was well established before anyone appreciated that the same receptor pathway aggressively drives breast cancer progression in adults. Receptor biology in one tissue context does not automatically translate to another, and GLP-1 receptor expression patterns across human tissues are still being mapped.

Dosing: What the Trials Used

The escalation schedule matters. Wilding et al.'s STEP 1 protocol used a four-step escalation from 0.25 mg weekly up to the 2.4 mg maintenance dose over 16 weeks, specifically designed to reduce gastrointestinal adverse events during dose titration. [5] Compressing that schedule to reach the therapeutic dose faster is not supported by trial data and is the most common source of the nausea and vomiting that drives early discontinuation.

Oral semaglutide is pharmacokinetically messier than the subcutaneous form. The PIONEER 11 trial, testing oral semaglutide 14 mg daily in a predominantly Chinese population with type 2 diabetes, produced an estimated HbA1c reduction of 1.5 percentage points versus placebo over 26 weeks. [6] The oral formulation requires co-administration with SNAC (sodium N-[8-(2-hydroxybenzoyl)aminocaprylate]) as an absorption enhancer, and inter-individual pharmacokinetic variability is considerably higher than with subcutaneous injection. Whether the oral formulation delivers the same cardiovascular protection as the injectable is precisely what the SOUL trial is designed to answer, with results expected in 2024-2025.

Safety: What We Know and What We Don’t

Gastrointestinal side effects are the primary tolerability problem. The STEP 1 trial reported nausea, vomiting, and diarrhea as the most common adverse events, and these were the main driver of discontinuation. The slow escalation schedule mitigates but does not eliminate this.

The thyroid signal deserves honest treatment. Semaglutide carries an FDA black-box warning for thyroid C-cell tumors. A 2024 narrative review in Thyroid concluded that rodent carcinogenicity data drove this warning, that human GLP-1 receptors are expressed at lower density in thyroid tissue than rodent receptors, and that clinical trial and observational data to date show low event rates with no conclusive evidence of elevated thyroid cancer risk in humans. [7] The rodent signal is real, the human translation is uncertain, and long-term thyroid cancer incidence data beyond five years of continuous exposure simply do not exist yet.

Lean mass loss is a genuine concern for older patients. A 2026 meta-analysis of GLP-1 receptor agonist trials combined with lifestyle interventions found a mean body-weight reduction of approximately 10 kg more than placebo, while noting that lean mass, physical function, and body composition outcomes require standardized future reporting because current trial designs handle them inconsistently. [8] Roughly 39% of total weight lost on semaglutide in the STEP trials is lean mass, comparable to caloric restriction alone, but in older adults already at risk of sarcopenia this is not a trivial consideration.

The optic neuropathy signal is real enough to take seriously. A 2025 systematic review found that GLP-1 receptor agonist use, predominantly semaglutide, was associated with a relative increase in non-arteritic anterior ischemic optic neuropathy (NAION) risk ranging from nonsignificant to fourfold across studies, with no causal link establishable due to the retrospective design of all available studies. [9] The FDA added this to the label in 2024. Whether this is a true drug effect, a consequence of rapid weight loss affecting intraocular pressure dynamics, or a detection artifact in a population already at elevated vascular risk remains unknown.

Where Semaglutide Sits Relative to Its Competitors

Tirzepatide produces larger weight loss. A 2023 meta-analysis of 10 RCTs enrolling 9,873 patients found tirzepatide produced statistically significant weight loss versus placebo and versus GLP-1 receptor agonists as a class, with the 15 mg dose in SURMOUNT-1 achieving approximately 22.5% mean body-weight reduction versus semaglutide’s roughly 15% in STEP 1. [10] No head-to-head cardiovascular outcomes trial between the two agents has yet reported, which means tirzepatide’s superiority in weight loss does not translate into established superiority in the outcomes that matter most to cardiologists and nephrologists.

Liraglutide is now a second-choice agent. A 2023 network meta-analysis of 10 GLP-1 receptor agonists added to metformin in type 2 diabetes ranked semaglutide 1.0 mg subcutaneous among the top agents for both HbA1c reduction (-1.57%) and body-weight reduction (-5.99 kg), consistently outperforming liraglutide. [11] Liraglutide 3 mg (Saxenda) achieves roughly 8% mean weight loss against semaglutide’s 15%, requires daily rather than weekly injection, and costs comparably in most markets. The clinical case for choosing liraglutide over semaglutide in a patient who tolerates either is thin.

What’s Coming That Will Actually Change the Picture

Heart failure with preserved ejection fraction. STEP-HFpEF showed semaglutide 2.4 mg improved Kansas City Cardiomyopathy Questionnaire scores and reduced CRP in 529 patients with HFpEF and obesity. A 2026 meta-analysis of six RCTs enrolling 5,564 HFpEF patients found that when older-generation agents like exenatide were excluded, newer GLP-1 receptor agonists showed a significant 41% reduction in heart failure events, though no significant effect on cardiovascular mortality was observed overall. [12] This is a preliminary signal in a population with very limited pharmacological options, and it is the most clinically meaningful near-term expansion of semaglutide’s indication.

Alzheimer’s disease. The evoke and evoke+ phase 3 trials are testing oral semaglutide versus placebo in early-stage symptomatic Alzheimer’s disease, with main phase completion expected in September 2025. [13] The biological rationale draws on GLP-1R expression in the central nervous system and preclinical data on neuroinflammation, but this remains an early-stage hypothesis in humans. If the evoke trials read out positive, the implications for the drug’s use would be extraordinary. A negative result would be equally important: silence from that outcome should not be read as license to use the drug off-label for cognitive protection.

The evidence base for semaglutide is genuinely strong where it has been tested in large, well-powered human trials. The temptation to extend that credibility to mechanisms and indications that remain preclinical is understandable, but it is exactly the kind of inferential leap that has embarrassed the field before. The drug doesn’t need the help.

[1]: Nephrology, dialysis, transplantation, 2026, meta-analysis of 19 RCTs (n=90,882).
[2]: Frontiers in endocrinology, 2024, review of GLP-1R mechanisms.
[3]: Signal Transduction and Targeted Therapy, 2024, review of GLP-1R expression and therapeutic applications.
[4]: International Journal of Molecular Sciences, 2026, review of endothelial damage and GLP-1RA pharmacological modulation.
[5]: Nature Medicine, 2023, SURMOUNT-3 RCT (n=579).
[6]: Diabetologia, 2024, PIONEER 11 RCT (n predominantly Chinese T2D population).
[7]: Thyroid, 2024, narrative review of GLP-1 RAs and thyroid cancer.
[8]: Nutrients, 2026, meta-analysis of GLP-1RA within lifestyle interventions.
[9]: Diabetes & Metabolism, 2025, systematic review of NAION and GLP-1 RA use.
[10]: PLoS ONE, 2023, meta-analysis of tirzepatide (10 RCTs, n=9,873).
[11]: Frontiers in Endocrinology, 2023, network meta-analysis of 10 GLP-1RAs in T2D.
[12]: Journal of Cardiovascular Development and Disease, 2026, meta-analysis of GLP-1 RAs in HFpEF (6 RCTs, n=5,564).
[13]: Alzheimer’s Research & Therapy, 2025, evoke/evoke+ trial design publication.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.

References

1. The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis.. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2026.

2. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.. Frontiers in endocrinology, 2024.

3. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.. Signal transduction and targeted therapy, 2024.

4. Biomarkers and Endothelial Damage in Obesity: An Insight into the Pharmacological Modulation.. International journal of molecular sciences, 2026.

5. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.. Nature medicine, 2023.

6. Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial.. Diabetologia, 2024.

7. Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review.. Thyroid : official journal of the American Thyroid Association, 2024.

8. GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis.. Nutrients, 2026.

9. What the diabetologist needs to know about the risk of non-arteritic anterior ischaemic optic neuropathy and GLP-1 receptor agonist use in patients with type 2 diabetes.. Diabetes & metabolism, 2025.

10. Weight loss efficiency and safety of tirzepatide: A Systematic review.. PloS one, 2023.

11. Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.. Frontiers in endocrinology, 2023.

12. Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.. Journal of cardiovascular development and disease, 2026.

13. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.. Alzheimer's research & therapy, 2025.